ArticleAntimicrobial agents and chemotherapy2005
Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 145 citations in OpenAlex.
- Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers.Antimicrobial agents and chemotherapy · 2017Trial
- The Convergence of Antimicrobial Resistance and Virulence inMicroorganisms · 2026Review
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review.European journal of medical research · 2026Review
- Review
- Characterization of an enterococcal phage endolysin as a potential antimicrobial agent against Streptococcus suis.Veterinary research · 2025Article
- Exploring the Therapeutic Potential: Antisense RNA Delivery Via Bacteriophage Platform.Iranian journal of biotechnology · 2025Review
- Bacteriophage-derived endolysins restore antibiotic susceptibility in β-lactam- and macrolide-resistant Streptococcus pneumoniae infections.Molecular medicine (Cambridge, Mass.) · 2025Article
- Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections.Pharmaceutics · 2025Review
- The Unique Capability of Endolysin to Tackle Antibiotic Resistance: Cracking the Barrier.Journal of xenobiotics · 2025Review
- Endolysins: targetingFrontiers in microbiology · 2025Review
- Synthetic mRNA delivered to human cells leads to expression of Cpl-1 bacteriophage-endolysin with activity againstMolecular therapy. Nucleic acids · 2024Article
- Phage Therapy, a Salvage Treatment for Multidrug-Resistant Bacteria Causing Infective Endocarditis.Biomedicines · 2023Review
- Expression of a recombinant endolysin from bacteriophage CAP 10-3 with lytic activity against Cutibacterium acnes.Scientific reports · 2023Article
- Therapeutic potential ofmSphere · 2023Article
- Review
- Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.Journal of biomedical science · 2023Review
- Identification of a phage-derived depolymerase specific for KL47 capsule of Klebsiella pneumoniae and its therapeutic potential in mice.Virologica Sinica · 2022Article
- Phage derived lytic peptides, a secret weapon againstFrontiers in medicine · 2022Article
- Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cpl-1, a pneumococcal phage lytic enzyme, was tested in rats with experimental endocarditis due to Streptococcus pneumoniae WB4. High-dose regimen Cpl-1 eliminated pneumococci from blood within 30 min and decreased bacterial titers in vegetations (>4 log10 CFU/g) within 2 h. Rapid bacterial lysis induced by Cpl-1 treatment increased cytokine secretion noticeably.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.